NRx Pharmaceuticals, Inc. (NRXP)

NASDAQ: NRXP · IEX Real-Time Price · USD
4.36
-0.03 (-0.68%)
At close: Jan 14, 2022 4:00 PM
4.38
0.02 (0.46%)
After-hours:Jan 14, 2022 7:08 PM EST
Market Cap256.41M
Revenue (ttm)n/a
Net Income (ttm)-369.87M
Shares Out58.81M
EPS (ttm)-20.22
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume610,395
Open4.35
Previous Close4.39
Day's Range4.30 - 4.47
52-Week Range4.07 - 64.20
Beta0.27
Analystsn/a
Price Targetn/a
Earnings DateNov 16, 2021

About NRXP

NRX Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company, develops various therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company's pipeline includes medicinal candidates in Phase 2 and Phase 3 trials for COVID-19-related lung injury and acute respiratory distress. Its products include ZYESAMI, an investigational pre-commercial drug for COVID-19 related respiratory failure; and NRX-100/101, an investigational pre-commercial drug for treating bipolar depres...

IndustryBiotechnology
Founded2015
Employees2
Stock ExchangeNASDAQ
Ticker SymbolNRXP
Full Company Profile

Financial Performance

Financial Statements

News

NRx Responds to Relief's Allegations of January 14, 2022

RADNOR, Pa., Jan. 14, 2022 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, responded to today's press release issued by Relief Therapeutics.

2 days ago - GlobeNewsWire

NRx Pharma Files Counterclaim Against Relief Therapeutics Over COVID-19 Candidate Rights

NRx Pharmaceuticals Inc (NASDAQ: NRXP) has filed a counterclaim against its former partner, Relief Therapeutics Holdings (OTC: RLFTF), in an ongoing dispute over the COVID-19 treatment Zyesami (avaptadi...

3 days ago - Benzinga

NRx Pharmaceuticals Files Counterclaim Against its Former Collaboration Partner, Relief Therapeutics

RADNOR, Pa. , Jan. 12, 2022 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP) filed a lawsuit on Monday against Relief Therapeutics (SIX: RLF, OTCQB: RLFTF, RLFTY), its former collaboration partner, in...

4 days ago - PRNewsWire

NRx Announces Planned Study Investigating BriLife™ Booster Vaccine Against Omicron Variant

RADNOR, Pa., Jan. 11, 2022 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, expanded on the information provided Monday at the H.C. Wainwright BioConn...

5 days ago - GlobeNewsWire

3 Reddit Penny Stocks For Your Watch List In January 2022

Reddit penny stocks to watch this week. The post 3 Reddit Penny Stocks For Your Watch List In January 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols:PTPIWTI
6 days ago - PennyStocks

NRx Pharmaceuticals to Announce New Details for Planned Investigational BriLife™ COVID-19 Vaccine

RADNOR, Pa., Jan. 07, 2022 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, today announced its Chairman of the Board and Chief Executive Officer, Pro...

1 week ago - GlobeNewsWire

NRx Pharmaceutical's Chairman and Chief Executive Officer Jonathan Javitt to Present Company Business Update at H.C. ...

RADNOR, Pa., Jan. 07, 2022 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, today announced its Chairman of the Board and Chief Executive Officer, Pro...

1 week ago - GlobeNewsWire

NRXP Stock Alert: The Covid-19 News Lifting NRx Pharmaceuticals Today

News of a potential Covid-19 treatment breakthrough has NRXP stock rising today. Here's what you need to know about this FDA filing.

1 week ago - InvestorPlace

NRx Pharmaceuticals Submits Emergency Use Authorization Application to US Food and Drug Administration for ZYESAMI® (...

RADNOR, Pa., Jan. 5, 2022 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP) announced today that it has submitted an application for Emergency Use Authorization (EUA) to the US Food and Drug Administra...

1 week ago - PRNewsWire

3 COVID Stocks That Could Double in 2022

Want a two-bagger this year? These three COVID stocks just might do it.

Other symbols:ADPTFLGT
1 week ago - The Motley Fool

NRx Pharmaceuticals Files Provisional Patent for Stable Compositions of Aviptadil Suitable for Human Use

RADNOR, Pa., Jan. 3, 2022 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP) announced today that it has filed a provisional composition of matter patent application with the US Patent and Trademark Off...

1 week ago - PRNewsWire

3 Biotech Stocks That Could Double in 2022

They're risky. But with the high risk comes the potential for high rewards.

Other symbols:ACETCCXI
1 week ago - The Motley Fool

NRXP Stock Alert: What Is Going on With NRx Pharmaceuticals Today?

NRx is seeking to have the FDA grant its coronavirus treatment breakthrough designation, based on new, favorable data on the drug. NRXP stock is climbing on the news.

2 weeks ago - InvestorPlace

Hot Penny Stocks To Watch Before Today's Opening Bell

These penny stocks are on the move, early and here's why. The post Hot Penny Stocks To Watch Before Today's Opening Bell appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks....

Other symbols:AVCTCANFYGMZ
2 weeks ago - PennyStocks

NRx Pharmaceuticals Files Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil) in Patients at Immediate ...

RADNOR, Pa., Dec. 29, 2021 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP) announced today that it has filed a new Breakthrough Therapy Designation (BTD) request with the US Food and Drug Administrat...

2 weeks ago - PRNewsWire

NRx Pharmaceuticals Added to the Nasdaq® Biotech Index

RADNOR, Pa., Dec. 15, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq: NRXP) today announced that Nasdaq (Nasdaq:NDAQ) has added the company to the Nasdaq Biotechnology Index (Nasdaq:NBI) effective...

1 month ago - GlobeNewsWire

NRx Pharmaceuticals Announces New, Favorable Safety Report for ZYESAMI® (aviptadil) in NIH Sponsored ACTIV-3b Critica...

RADNOR, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq: NRXP ), a clinical-stage, biopharmaceutical company, today provided a new safety update on ZYESAMI® (aviptadil), which is bein...

1 month ago - GlobeNewsWire

NRx Pharmaceuticals and Hungarian Health Officials Agree on Pathway for ZYESAMI® and BriLife COVID-19 Vaccine Trials

BUDAPEST, Hungary, Dec. 09, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ:  NRXP ) today announced the conclusion of high-level meetings in Hungary that are expected to lead to utilization of ZYE...

1 month ago - GlobeNewsWire

NRx Announces Completion of Data Safety Meeting for Phase 2 Trial of BriLife Vaccine, Phase 2b/3 Registration Trial t...

RADNOR, Pa., Dec. 06, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ:  NRXP ), today was advised that the independent Data Safety Monitoring Board overseeing the phase 2 trial of the BriLife™ vacc...

1 month ago - GlobeNewsWire

Why NRx Pharmaceuticals Stock Soared Today

Investors are intrigued by the potential of the drugmaker's experimental coronavirus therapy.

1 month ago - The Motley Fool

3 Incredibly Cheap Growth Stocks That Could Make You a Millionaire

Bionano Genomics, BioCryst Pharmaceuticals, and NRx Pharmaceuticals all have the potential to make their early shareholders rich.

Other symbols:BCRXBNGO
1 month ago - The Motley Fool

NRXP Stock Surges on Latest Covid-19 Update From NRx Pharmaceuticals

News that NRx Pharmaceuticals' Covid-19 treatment helps improve survivability in critical patients is sending NRXP stock higher today. The post NRXP Stock Surges on Latest Covid-19 Update From NRx Pharm...

1 month ago - InvestorPlace

Why Are NRx Pharma's Shares Soaring Premarket?

NRx Pharmaceuticals (NASDAQ: NRXP) has completed an analysis in the subgroup of Zyesami and placebo-treated patients previously treated with Gilead Science Inc's (NASDAQ: GILD) remdesivir in the COVID-A...

1 month ago - Benzinga

NRx Pharmaceuticals Identifies Significantly Higher Likelihood of Surviving and Recovering from Critical COVID-19 in ...

RADNOR, Pa., Nov. 29, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq: NRXP) announced today that it has completed an analysis to identify clinical evidence that indicates a substantial improvement...

1 month ago - GlobeNewsWire

NRx Pharma Skyrockets After BriLife COVID-19 Vaccine Data Against Delta Variant

Israel Institute for Biological Research (IIBR) has posted scientific results from an initial sample of Phase 2 vaccinated patients to assess the BriLife vaccine against the COVID-19 Delta variant. Bloo...

1 month ago - Benzinga